Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Plasma YKL-40 as a biomarker for poor prognosis in patients with metastatic colorectal cancer treated with 3. line cetuximab and irinotecan

Date

10 Oct 2016

Session

Poster display

Presenters

Benny Jensen

Citation

Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363

Authors

B.V. Jensen1, K.G. Spindler2, I.J. Christensen3, J.V. Schou4, D.L. Nielsen1, A. Jakobsen5, E. Høgdall3, P. Pfeiffer6, M.K. Yilmaz7, J. Johansen1

Author affiliations

  • 1 Department Of Oncology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 2 Oncology, Aarhus University Hospital, 8000 - Aarhus/DK
  • 3 Department Of Pathology, Herlev and Gentofte Hospital, 2730 - Herlev/DK
  • 4 Department Of Oncology, Herlev and Gentofte Hospital, 2730 - Copenhagen/DK
  • 5 Oncology, Vejle Hospital Sygehus Lillebaelt, Vejle Sygehus, 7100 - Vejle/DK
  • 6 Department Of Oncology, Odense University Hospital, 5000 - Odense C/DK
  • 7 Department Of Oncology, Aalborg University Hospital, 9100 - Aalborg/DK
More

Resources

Background

YKL-40 (CHI3L1) plays a major role in inflammation and angiogenesis. In patients with metastatic colorectal cancer (mCRC) we wanted to test if high pretreatment levels of plasma YKL-40 and change of YKL-40 during therapy with cetuximab and irinotecan was independent of KRAS mutation status and associated with progression free (PFS) and overall survival (OS).

Methods

Two independent studies of 162 patients and 98 patients (Study I and II) with mCRC resistant to 5-FU, oxaliplatin and irinotecan treated with cetuximab and irinotecan without knowledge of their KRAS mutation status were performed in Denmark between 2006 and 2008. Plasma YKL-40 was determined by ELISA. Seven mutations in the KRAS oncogene were determined by the DxS TheraScreen kit.

Results

In both studies a high pretreatment plasmaYKL-40 (log transformed continuous variable) was significantly associated to short overall survival (OS) independent of KRAS mutation status (Study I: HR = 1.17, 95% CI 1.04-1.30, P = 0.009; interaction between KRAS and YKL-40 P = 0.75; Study II: HR = 1.34, 95% CI 1.12-1.59, P = 0.0001; interaction between KRAS and YKL-40 p = 0.85). Multivariate Cox analysis including YKL-40, age, sex, performance status (PS), number of metastatic sites and KRAS mutation status demonstrated that elevated pretreatment plasma YKL-40 was an independent biomarker of OS (Study I: HR = 1.53, 95% CI 1.10-2.13, P = 0.013; Study II: HR = 2.89, 1.84-4.53, P 

Conclusions

In two independent studies plasma YKL-40 before and during treatment of patients with mCRC with cetuximab and irinotecan was a strong independent biomarker of PFS and OS independent of KRAS mutation status.

Clinical trial identification

EudraCT number 2006-001-961-40

Legal entity responsible for the study

Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen

Funding

Department of Oncology, Herlev and Gentofte Hospital, University of Copenhagen

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings